Denali Therapeutics Inc. (DNLI) Shareholder/Analyst Call Transcript

Denali Therapeutics Inc. (DNLI) Shareholder/Analyst Call Transcript

Seeking Alpha • Feb 6, 2026

Denali Therapeutics Presents Enzyme TransportVehicle™ Progress Across Three Clinical Programs for Treatment of Lysosomal Storage Disorders at 2026 WORLDSymposium™

SOUTH SAN FRANCISCO, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced data from programs in Hunter syndrome (mucopolysaccharidosis type II, MPS II), Sanfilippo syndrome type A (MPS IIIA) and Pompe disease that highlight the potential of its Enzyme TransportVehicle™ (ETV) to enable the delivery of enzyme replacement therapies (ERT) to the whole body, including the brain. Data were presented this week at the 22nd Annual WORLDSymposium™ in San Diego, California.

GlobeNewsWire • Feb 5, 2026

5 Drug/Biotech Stocks Likely to Outperform Q4 Earnings Estimates

Let us look at some drug/biotech stocks, ZTS, PCRX, APLS, ACAD and DNLI, which are poised to beat on fourth-quarter 2025 earnings.

Zacks Investment Research • Feb 3, 2026

Denali Therapeutics To Host Webcast Highlighting Presentations on Enzyme TransportVehicle™ Programs at the 2026 WORLDSymposium™

SOUTH SAN FRANCISCO, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that management will host a live webcast to review presentations on its Enzyme TransportVehicle™ (ETV) programs at the upcoming 22nd Annual WORLDSymposium™ being held February 2-6, 2026, in San Diego, California. These presentations will demonstrate the broad potential of the ETV to enable the delivery of enzyme replacement therapies to the whole body, including the brain. Titles and times for the presentations were previously announced in a corporate news release here. The live webcast will begin at 12:30 p.m. Pacific Time on Thursday, February 5, 2026, and can be accessed on the Events page of the Investor section on Denali's corporate website at https://investors.denalitherapeutics.com/events or click here.

GlobeNewsWire • Feb 2, 2026

Denali Therapeutics Announces Data Presentations on Enzyme TransportVehicle™ Programs for Hunter Syndrome, Sanfilippo Syndrome Type A and Pompe Disease at Upcoming 2026 WORLDSymposium™

SOUTH SAN FRANCISCO, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced the presentation of clinical and preclinical data from its Enzyme TransportVehicle™ (ETV) programs at the upcoming 22nd Annual WORLDSymposium™ to be held February 2-6, 2026, in San Diego, California. These presentations will demonstrate the broad potential of the ETV to enable the delivery of enzyme replacement therapies to the whole body, including the brain.

GlobeNewsWire • Jan 29, 2026

3 Biotech Stocks That Could Double In 2026

The biotech sector is one that's become red-hot, at least in recent years. After around a decade of stagnation, investors appear to be intent on increasing their exposure to top biotech names in the market, as growth in other sectors of the economy have led to valuations that now look more elevated than the biotech sector (in many cases).

24/7 Wall Street • Jan 20, 2026

Denali Therapeutics Inc. (DNLI) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Denali Therapeutics Inc. (DNLI) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Seeking Alpha • Jan 14, 2026

Denali Therapeutics Unveils Portfolio Goals for 2026, Stock Up

DNLI maps 2026 goals as it awaits FDA action on tividenofusp alfa, targeting first commercial validation amid multiple late-stage readouts.

Zacks Investment Research • Jan 7, 2026

The New England Journal of Medicine Publishes Phase 1/2 Study of Denali Therapeutics' Tividenofusp Alfa (DNL310) for Hunter Syndrome (MPS II)

SOUTH SAN FRANCISCO, Calif., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced the publication of results from the open-label Phase 1/2 clinical trial of its investigational, next-generation enzyme replacement therapy (ERT), tividenofusp alfa (DNL310), for the treatment of Hunter syndrome (mucopolysaccharidosis type II, or MPS II) in the January 1, 2026 issue of The New England Journal of Medicine. The U.S. Food and Drug Administration (FDA) is conducting a Priority Review of the Biologics License Application (BLA) for tividenofusp alfa, which is supported by these data and for which Denali is seeking accelerated approval. A decision by the FDA on the tividenofusp alfa BLA is expected by April 5, 2026.

GlobeNewsWire • Dec 30, 2025

3 Biotech Stocks With Major 2026 Catalysts

Biotech's 2025 rebound sets the stage for Denali Therapeutics and two peers, with key FDA decisions and pipeline catalysts lined up for 2026.

Zacks Investment Research • Dec 29, 2025